Correction: Characterization of Human Mesenchymal Stem Cells from Ewing Sarcoma Patients. Pathogenetic Implications

Amaral, Ana Teresa et al.[Background] Ewing Sarcoma (EWS) is a mesenchymal-derived tumor that generally arises in bone and soft tissue. Intensive research regarding the pathogenesis of EWS has been insufficient to pinpoint the early events of Ewing sarcomagenesis. However, the Mesenchymal Stem Cell (MSC) is currently accepted as the most probable cell of origin.[Materials and Methods] In an initial study regarding a deep characterization of MSC obtained specifically from EWS patients (MSC-P), we compared them with MSC derived from healthy donors (MSC-HD) and EWS cell lines. We evaluated the presence of the EWS-FLI1 gene fusion and EWSR1 gene rearrangements in MSC-P. The presence of the EWS transcript was confirmed by q-RT-PCR. In order to determine early events possibly involved in malignant transformation, we used a multiparameter quantitative strategy that included both MSC immunophenotypic negative/positive markers, and EWS intrinsic phenotypical features. Markers CD105, CD90, CD34 and CD45 were confirmed in EWS samples.[Results] We determined that MSC-P lack the most prevalent gene fusion, EWSR1-FLI1 as well as EWSR1 gene rearrangements. Our study also revealed that MSC-P are more alike to MSC-HD than to EWS cells. Nonetheless, we also observed that EWS cells had a few overlapping features with MSC. As a relevant example, also MSC showed CD99 expression, hallmark of EWS diagnosis. However, we observed that, in contrast to EWS cells, MSC were not sensitive to the inhibition of CD99.[Conclusions] In conclusion, our results suggest that MSC from EWS patients behave like MSC-HD and are phenotypically different from EWS cells, thus raising important questions regarding MSC role in sarcomagenesis. © 2014 Amaral et al.Research in Enrique de Alava's lab is supported by the Ministry of Science and Innovation of Spain-FEDER (PI081828, RD06/0020/0059, PI110018, ISCIII, postdoc grant CD06/00001 to JLOG), the Fundação para a Ciência e Tecnologia, Ministério para a Investigação e Tecnologia, Portugal (ATA fellowship SFRH/BD/69318/2010) and the Red Temática de investigación del cáncer (RTICC, Spain). This work was also supported by the European Commission (FP7-HEALTH-2011-two-stage, Project ID 278742 EUROSARC). Katia Scotlandi's lab is also funded by AIRC, Italian Association for Cancer Research, (project 10452 to KS), Progetto FIRB- Accordi di programma 2010 COD, RBAP10447, and by the Italian Ministry of Health (Project IOR-2006-422755).Peer reviewe